Synairgen PLC (AIM:SNG, OTC:SYGGF) said a Covid clinical trial led by a US government agency had returned encouraging data from a phase II evaluation of the UK group’s lead asset.
The National Institutes of Health (NIH) oversaw the ACTIV-2 study to assess SNG001’s impact on home-based sufferers of the virus.
It found that only one of the 110 people receiving the Synairgen broad-spectrum antiviral had to be subsequently hospitalised compared with seven in the control group. While the relative risk reduction was 86%, it was not deemed statistically significant.
SNG001 was also found to be well tolerated and had a "favourable" safety profile.
"These results are really encouraging and build upon the strong body of non-clinical and clinical evidence, which includes Synairgen's home-based trial (SG016) in high-risk patients, supporting SNG001's potential as a broad-spectrum antiviral for a wide range of severe lung infections including Covid-19,” said Synairgen chief executive Richard Marsden.
“We will now begin to evaluate the full data set and factor these findings into our development plans."